Infant Bacterial Therapeutics
35
SEK
+2,94 %
Mindre end 1K følgere
IBT B
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Finansielt overblik og estimater
Ownership
+2,94%
-18,03%
-34,7%
-35,19%
0%
-55,01%
-32,04%
-55,97%
-40,13%
Infant Bacterial Therapeutics is a biotechnology company focused on developing innovative treatments for inflammatory bowel diseases. The company develops, among other things, medicines to treat and prevent common conditions and diseases in children that occur at early birth. The business is global with a primary presence in Europe and North America. Infant Bacterial Therapeutics was founded in 2010 and is headquartered in Stockholm, Sweden.
Læs mereMarkedsværdi
471,5 mio. SEK
Aktieomsætning
446,19 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Finanskalender
7.5
2025
Delårsrapport Q1'25
8.5
2025
Generalforsamling '25
20.8
2025
Delårsrapport Q2'25
Alle
Selskabsmeddelelser
ViserAlle indholdstyper
IBT Continues Development of Drug Candidate IBP-9414
Infant Bacterial Therapeutics AB (publ) Interim report January 1 – September 30, 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools